What is the most likely treatment for Alzheimer's?
By Kim, Jin-Gu | translator Choi HeeYoung
21.06.10 06:19:07
가나다라
0
Inspection on the Development Status of Alzheimer's Treatment in '2021 Bio Korea'
GemVax & KAEL and Aribio among domestic companies are in the preparation stage of Phase III clinical trials
Global development of Roche, Lilly, and Eisai is nearing its end
▲With 2021 Bio Korea held on the 9th, an innovative strategy session is being held for early diagnosis and treatment of Alzheimer
As Biogen's Aducanumab (Aduhel) was approved by the U.S. Food and Drug Administration (FDA) for the first time in 18 years as a treatment for Alzheimer's, competition for development of Aducanumab.
Currently, Roche, Eli Lilly, Ezai, Johnson and Johnson are considered companies that have started to develop treatments for Alzheimer's. In Korea, GemVax & KAEL and Aribio, Ildong, MEDIPOST, and Hyundai are developing dementia drugs. Among them, Zembax and Aribio are said to be fast in development.
At the "2021 Bio Korea" held at COEX in Seoul on the 9th, the current status of development of Alzheimer's drugs at home and abroad was discussed under the theme of "Innovative Strategies fo
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)